Prenetics Global Limited (NASDAQ:PRE – Get Free Report) CFO Brian Rosin bought 18,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were acquired at an average price of $21.19 per share, for a total transaction of $381,420.00. Following the completion of the transaction, the chief financial officer owned 18,000 shares in the company, valued at $381,420. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Prenetics Global Price Performance
PRE opened at $26.25 on Friday. Prenetics Global Limited has a fifty-two week low of $7.27 and a fifty-two week high of $26.50. The company’s 50 day moving average price is $19.36 and its two-hundred day moving average price is $19.03. The firm has a market capitalization of $442.94 million, a price-to-earnings ratio of -6.31 and a beta of 0.26.
Prenetics Global (NASDAQ:PRE – Get Free Report) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. As a group, equities research analysts predict that Prenetics Global Limited will post -1.86 EPS for the current year.
Institutional Trading of Prenetics Global
Analyst Upgrades and Downgrades
PRE has been the topic of a number of analyst reports. B. Riley Financial started coverage on Prenetics Global in a research report on Thursday. They issued a “buy” rating and a $37.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Benchmark upped their target price on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.80.
Check Out Our Latest Research Report on Prenetics Global
Key Stories Impacting Prenetics Global
Here are the key news stories impacting Prenetics Global this week:
- Positive Sentiment: IM8 CEO Danny Yeung and CFO Brian Rosin purchased approximately $1.0 million of Prenetics shares in open-market transactions between August 20 and August 25, following the release of second-quarter results. Company leadership’s cumulative personal investment since November 2025 has reached roughly $3.75 million, providing a strong insider-confidence signal. Prenetics IM8 CEO and CFO Purchase $1.0 Million of Shares
- Positive Sentiment: B. Riley Financial initiated coverage of PRE with a “buy” rating and a $37 price target, implying approximately 41% upside from the referenced share price. The new coverage adds to a generally favorable analyst view; four analysts rate the stock Buy and one rates it Sell, with a consensus target of $34.25. B. Riley initiates coverage of Prenetics Global
- Positive Sentiment: CFO Brian Rosin separately bought 18,000 shares at an average $21.19 and another 5,100 shares at $22.80, investing about $497,700 in total and increasing his ownership substantially. These purchases were disclosed in SEC filings and reinforce the broader insider-buying catalyst. Insider Buying: Prenetics Global CFO Purchases Shares
- Neutral Sentiment: Prenetics reported second-quarter EPS of negative $0.53, better than the expected negative $0.84, but revenue of $46.49 million missed the $49.85 million consensus estimate. The company remains loss-making, with a negative net margin and analysts forecasting a full-year loss.
- Negative Sentiment: The stock is trading near its 52-week high after a sharp advance, which may increase valuation and profit-taking risks if Prenetics does not accelerate revenue growth or improve profitability.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Featured Articles
- Five stocks we like better than Prenetics Global
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
